Droperidol Aguettant: Uses, Dosage & Side Effects

What Is Droperidol Aguettant and What Is It Used For?

Droperidol Aguettant contains the active substance droperidol, a butyrophenone derivative that has been in clinical use since the 1960s. Butyrophenones are a class of neuroleptic (antipsychotic) drugs that share a common chemical structure and pharmacological profile, with droperidol being one of the most well-known members alongside haloperidol. Droperidol was originally developed as a component of neuroleptanalgesia—a technique combining a neuroleptic with a potent opioid analgesic to achieve a state of sedation and analgesia during surgical procedures. While the practice of neuroleptanalgesia has largely been replaced by modern anaesthetic techniques, droperidol has found a central role in contemporary perioperative medicine as one of the most effective and cost-efficient antiemetic agents available.

The antiemetic properties of droperidol are mediated primarily through its potent antagonism of dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the area postrema, a circumventricular organ located in the medulla oblongata at the floor of the fourth ventricle. The CTZ lies outside the blood-brain barrier, making it accessible to circulating emetogenic substances such as anaesthetic agents, opioid analgesics, and metabolic byproducts. By blocking the dopamine D2 receptors in this region, droperidol effectively interrupts the neural signaling cascade that leads to nausea and the emetic reflex. In addition to its primary dopaminergic mechanism, droperidol also exhibits weak antagonism at serotonin 5-HT2 receptors, alpha-1 adrenergic receptors, and histamine H1 receptors, which may contribute to its broad antiemetic efficacy and its sedative and anxiolytic properties.

The primary clinical indications for Droperidol Aguettant include the following:

• Prevention of postoperative nausea and vomiting (PONV): Droperidol is one of the most extensively studied antiemetics for PONV prophylaxis. A Cochrane systematic review encompassing over 80 randomized controlled trials demonstrated that low-dose droperidol (0.625–1.25 mg IV) reduces the relative risk of PONV by approximately 35–50% compared with placebo. This efficacy is comparable to that of ondansetron (4 mg IV), the most commonly used 5-HT3 receptor antagonist. International consensus guidelines from the Society for Ambulatory Anesthesia (SAMBA) and the European Society of Anaesthesiology and Intensive Care (ESAIC) recommend droperidol as a first-line antiemetic option for patients at moderate-to-high risk of PONV.
• Treatment of established PONV: In patients who develop nausea or vomiting after surgery despite prophylaxis or without prophylaxis, low-dose droperidol can be administered as a rescue antiemetic, particularly if a different class of antiemetic was used for prophylaxis.
• Preoperative sedation and anxiolysis: Due to its sedative, anxiolytic, and antiemetic properties, droperidol is used as a premedication before surgical and diagnostic procedures. At low doses, it produces a state of calm and reduced anxiety without significant respiratory depression, which makes it useful as an adjunct to other premedication agents.
• Management of acute agitation: In emergency medicine, droperidol is used for the rapid tranquillisation of acutely agitated patients, including those with acute psychosis, substance intoxication, or severe behavioural disturbance. Multiple randomized trials and systematic reviews have demonstrated that intramuscular droperidol (5–10 mg) achieves rapid sedation within 15–30 minutes with a favourable safety profile compared to alternatives such as haloperidol or midazolam.
• Adjunct to patient-controlled analgesia (PCA): Low-dose droperidol (0.05–0.1 mg per mL) is sometimes added to opioid PCA solutions to reduce opioid-induced nausea and vomiting in postoperative patients, although this use is less common in current practice.

Droperidol has been included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance, established efficacy, safety profile at recommended doses, and cost-effectiveness in global health. The 1.25 mg/mL formulation by Aguettant is designed for direct intravenous or intramuscular administration and is available in ampoules suitable for single-patient use. After intravenous injection, droperidol has a rapid onset of action within 3–10 minutes, with a peak antiemetic effect at approximately 30 minutes and a clinical duration of effect of 2–4 hours for its antiemetic action, though sedative effects may persist somewhat longer.

What Should You Know Before Taking Droperidol Aguettant?

Contraindications

Droperidol Aguettant must not be used in the following situations, as administration could pose a serious risk to patient safety:

• Known QT interval prolongation: Droperidol is contraindicated in patients with known or suspected QT prolongation on the electrocardiogram, including congenital long QT syndrome (e.g., Romano-Ward syndrome, Jervell and Lange-Nielsen syndrome). QT prolongation increases the risk of life-threatening ventricular arrhythmias, including torsades de pointes.
• Hypokalemia and hypomagnesemia: Electrolyte imbalances, particularly low serum potassium and magnesium levels, potentiate the QT-prolonging effect of droperidol and increase the risk of cardiac arrhythmias. Electrolyte levels should be corrected before administration.
• Phaeochromocytoma: Droperidol may precipitate a hypertensive crisis in patients with catecholamine-secreting tumours due to paradoxical alpha-adrenergic effects. This is a well-documented class effect of butyrophenone antipsychotics.
• Severe depression or comatose states: The CNS depressant properties of droperidol may worsen existing depression or further depress consciousness, particularly in combination with other sedative agents.
• Hypersensitivity: Known hypersensitivity to droperidol, other butyrophenones, or any of the excipients in the formulation.
• Parkinson's disease: Droperidol may exacerbate the symptoms of Parkinson's disease through its dopamine D2 receptor blocking activity. Use in patients with parkinsonism should be avoided.
• Concomitant use of QT-prolonging drugs: Droperidol should not be administered together with other medications known to prolong the QT interval, including class IA and III antiarrhythmics (e.g., amiodarone, sotalol, quinidine), certain antibiotics (e.g., erythromycin, moxifloxacin), and other antipsychotics (e.g., haloperidol, pimozide).

Warnings and Precautions

Before and during treatment with Droperidol Aguettant, several important precautions should be considered by the administering healthcare professional:

Cardiovascular monitoring: The most clinically significant concern with droperidol is dose-dependent QT interval prolongation. A 12-lead ECG should be obtained before administration in patients with cardiac risk factors, and continuous ECG monitoring is recommended during and for 30 minutes after intravenous administration in these patients. Risk factors for QT prolongation include a history of cardiac arrhythmias, heart failure, bradycardia, cardiac hypertrophy, electrolyte disturbances, and concomitant use of medications that may affect cardiac repolarisation. At the low doses used for PONV prophylaxis (0.625–1.25 mg), the QT-prolonging effect is generally minimal and clinically insignificant in patients without risk factors; however, vigilance remains appropriate.

Hypotension: Droperidol can cause hypotension, particularly in hypovolemic patients or when administered concomitantly with other agents that lower blood pressure, such as opioid analgesics or anaesthetic agents. Blood pressure monitoring is recommended, and intravenous fluids should be available for volume replacement if needed. The risk of hypotension is greater with higher doses.

Neuroleptic malignant syndrome (NMS): As with all dopamine receptor antagonists, droperidol carries a rare but potentially fatal risk of neuroleptic malignant syndrome, characterised by hyperthermia, muscle rigidity, altered consciousness, and autonomic instability. If NMS is suspected, droperidol should be immediately discontinued and supportive care including cooling measures and dantrolene should be initiated.

Extrapyramidal symptoms: Droperidol may cause extrapyramidal reactions, including dystonia, akathisia, and oculogyric crisis, particularly at higher doses and in younger patients. These reactions are generally responsive to anticholinergic agents such as benztropine or diphenhydramine.

Elderly patients: Older adults are more susceptible to the sedative and hypotensive effects of droperidol. Dose reduction is recommended, and careful monitoring of haemodynamic parameters and level of consciousness is advised. Elderly patients may also be at increased risk of QT prolongation due to age-related changes in cardiac electrophysiology.

Pregnancy and Breastfeeding

Droperidol should only be used during pregnancy if the potential benefit to the mother clearly justifies the potential risk to the fetus. Animal reproductive toxicity studies have shown some evidence of harm at high doses, although direct teratogenic effects have not been consistently demonstrated. Droperidol crosses the placental barrier and may cause transient extrapyramidal symptoms and sedation in the newborn if administered near the time of delivery. If used during labour and delivery, the neonate should be monitored for respiratory depression, feeding difficulties, and neurological signs.

Droperidol is excreted in breast milk, and breastfeeding is not recommended during treatment and for a period after administration. If a single low dose is given for PONV prophylaxis, the clinical significance of breast milk exposure is likely minimal, but a risk-benefit discussion with the patient is recommended. For repeated or higher doses, breastfeeding should be temporarily discontinued.

How Does Droperidol Aguettant Interact with Other Drugs?

As a dopamine D2 receptor antagonist with secondary activity at other receptor types, droperidol has the potential for pharmacodynamic interactions with a wide range of medications. The most clinically significant interactions involve additive effects on cardiac repolarisation and central nervous system depression. Healthcare professionals should carefully review the patient's complete medication list before administering droperidol. The following table summarises the most important drug interactions:

Major Interactions

Minor Interactions

Because droperidol is metabolised in the liver primarily by cytochrome P450 enzymes CYP1A2 and CYP3A4, pharmacokinetic interactions may occur with strong inhibitors of these enzymes (e.g., ketoconazole, fluvoxamine, ciprofloxacin), potentially increasing droperidol plasma levels and prolonging its effects. However, given that droperidol is typically administered as a single low-dose injection in the perioperative setting, these pharmacokinetic interactions are generally of limited clinical significance compared to the pharmacodynamic interactions described above.

What Is the Correct Dosage of Droperidol Aguettant?

Droperidol Aguettant is a prescription-only medication that must be administered by or under the direct supervision of a qualified healthcare professional in an appropriate clinical setting with resuscitation facilities available. The dose, route of administration, and monitoring requirements depend on the clinical indication, the patient's age, weight, general condition, and concomitant medications. The following dosing recommendations are based on international guidelines and the approved Summary of Product Characteristics:

Adults

Children (over 2 years of age)

Elderly

Elderly patients (over 65 years) are generally more sensitive to the pharmacological effects of droperidol, including sedation, hypotension, and QT prolongation. Dose reduction is recommended in this population. For PONV prophylaxis, an initial dose of 0.625 mg IV is recommended. The dose should be titrated carefully, and haemodynamic and ECG monitoring is advised. Higher doses for agitation management should be used with extreme caution and at reduced dosages (2.5–5 mg IM) with close monitoring.

Missed Dose

Because droperidol is administered by healthcare professionals in controlled clinical settings (operating theatre, recovery room, emergency department), missed doses are not a typical concern. If a dose is not given at the intended time (e.g., at the end of surgery), it may still be administered in the recovery room if the patient develops nausea or vomiting, provided that contraindications have been excluded and appropriate monitoring is available.

Overdose

Droperidol overdose may manifest with excessive sedation, hypotension, extrapyramidal symptoms (muscle rigidity, tremor, dystonia, oculogyric crisis), respiratory depression, and QT prolongation with risk of ventricular arrhythmias. There is no specific antidote for droperidol overdose. Management is supportive and symptomatic:

• Airway management: Ensure a patent airway and provide assisted ventilation if respiratory depression occurs.
• Cardiovascular support: Intravenous fluids for hypotension; norepinephrine (not epinephrine) may be used as a vasopressor if needed, as epinephrine may cause paradoxical hypotension due to droperidol's alpha-blocking properties.
• ECG monitoring: Continuous cardiac monitoring for QT prolongation and arrhythmias. Intravenous magnesium sulfate and isoproterenol may be used for torsades de pointes; overdrive pacing may be necessary in refractory cases.
• Extrapyramidal symptoms: Treat with intravenous anticholinergic agents (benztropine 1–2 mg or diphenhydramine 25–50 mg).

What Are the Side Effects of Droperidol Aguettant?

Like all medicines, Droperidol Aguettant can cause side effects, although not everybody gets them. The nature and frequency of side effects are closely related to the dose administered. At the low doses used for antiemetic prophylaxis (0.625–1.25 mg), the side effect profile is generally favourable and comparable to other first-line antiemetics. At higher doses used for sedation and agitation management, side effects become more frequent and potentially more serious. The side effects are classified below by frequency according to the Medical Dictionary for Regulatory Activities (MedDRA) convention:

If you experience any side effects after receiving droperidol, inform your healthcare team immediately. In particular, symptoms suggestive of a cardiac arrhythmia (palpitations, irregular heartbeat, feeling faint, chest pain) or an allergic reaction (difficulty breathing, swelling of the face or throat, widespread rash) require urgent medical attention. Extrapyramidal symptoms, while distressing, are generally reversible with appropriate treatment (anticholinergic agents).

Healthcare professionals should report suspected adverse reactions to their national pharmacovigilance system (e.g., Yellow Card Scheme in the UK, MedWatch in the USA, EudraVigilance in the EU) to contribute to the ongoing safety monitoring of droperidol.

How Should You Store Droperidol Aguettant?

Droperidol Aguettant is a hospital and clinical-use medication, and proper storage is the responsibility of the dispensing pharmacy, nursing staff, or other designated healthcare professionals. The following storage conditions apply to this formulation:

• Temperature: Store below 25°C (77°F). Do not freeze. Droperidol solution is sensitive to extreme temperatures, and exposure to heat or freezing may alter its chemical stability and potency.
• Light protection: Keep the ampoules in the original outer carton to protect from light. Droperidol is a light-sensitive compound, and prolonged exposure to ambient or direct light may cause degradation of the active substance.
• Shelf life: The shelf life of Droperidol Aguettant 1.25 mg/mL solution for injection is typically 3 years when stored in the original packaging under the recommended conditions. Always check the expiry date on the ampoule and outer carton before use.
• After opening: Droperidol Aguettant ampoules are intended for single use only. Any unused solution remaining after withdrawal of the required dose should be discarded immediately. The product does not contain antimicrobial preservatives and should not be stored after opening.
• Diluted solutions: If droperidol is diluted in compatible infusion solutions (0.9% sodium chloride, 5% glucose, or Ringer's lactate), chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. However, from a microbiological standpoint, diluted solutions should be used immediately after preparation. If not used immediately, storage times and conditions are the responsibility of the user.
• Disposal: Keep out of the sight and reach of children. Do not use this medicine after the expiry date stated on the packaging. Unused medicine or waste material should be disposed of in accordance with local hospital pharmaceutical waste procedures and environmental regulations.

As a controlled hospital medication, patients do not typically handle droperidol for storage purposes. However, patients being discharged after receiving droperidol should be informed that the sedative effects may persist for several hours and that they should not drive, operate heavy machinery, or make important decisions for at least 24 hours after administration.

What Does Droperidol Aguettant Contain?

Droperidol Aguettant is a clear, colourless to slightly yellow, sterile, preservative-free solution for injection. The complete composition of the product is as follows:

Active Ingredient

• Droperidol: 1.25 mg per millilitre (mg/mL). Droperidol is a butyrophenone-class compound with the chemical name 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one. Its molecular formula is C₂₂H₂₂FN₃O₂ and its molecular weight is 379.43 g/mol. The compound is practically insoluble in water and is formulated as a solution using appropriate co-solvents and pH adjustment.

Excipients (Inactive Ingredients)

• Mannitol: Used as a tonicity agent to make the solution isotonic with body fluids, ensuring compatibility with intravenous and intramuscular administration. Mannitol also serves as a stabiliser for the droperidol in solution.
• Tartaric acid: Used as a buffering agent to maintain the pH of the solution within the optimal range for stability and tolerability. The pH of the final solution is approximately 3.0–3.8.
• Sodium hydroxide: Used for pH adjustment during manufacture to achieve the target pH range.
• Water for injections: The vehicle for the injectable solution, meeting pharmacopoeial standards for sterility, pyrogenicity, and particulate matter.

The product is supplied in glass ampoules, typically containing 1 mL (1.25 mg droperidol) or 2 mL (2.5 mg droperidol) of solution. The ampoules are made of type I colourless glass, which is the most chemically inert glass type and is suitable for parenteral preparations. The product does not contain latex, preservatives, or antimicrobial agents.

Droperidol Aguettant is physically and chemically compatible with commonly used intravenous infusion solutions, including 0.9% sodium chloride solution, 5% glucose solution, and Ringer's lactate solution. However, it should not be mixed with other medicinal products in the same syringe unless compatibility has been confirmed, as droperidol is slightly acidic and may be incompatible with alkaline solutions such as barbiturate preparations.